top of page
Search

Johnson & Johnson Invests in Orasis' QLOSI™ eyedrops



When Johnson & Johnson learned of the groundbreaking work from Orasis Pharmaceuticals, an emerging ophthalmic pharmaceuticals company, they knew it has the potential to be an excellent complement to their existing expertise in solutions to treat presbyopia, or loss of near vision, in adults. On September 19, 2024, J&J closed a transaction as the co-lead investor of Series D funding in Orasis Pharmaceuticals, creators of the QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, prescription eye drops, for presbyopes seeking a break from readers.


Comentarios


Maverick Ventures Israel, 26 Nachmani Street, Tel Aviv, Israel 

© 2019 by Ventures Mavericks (Israel)

bottom of page